Cerevance Media Center
Solengepras Leads the Shift Beyond Dopamine
Current News
February 1, 2021
Cerevance Appoints Carrie Ann Cook as Chief Business Officer
Cerevance, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer
December 8, 2020
Cerevance Appoints David Lubner to Board of Directors
Cerevance today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance’s Board of Directors.
November 16, 2020
Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
Cerevance today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS).
July 21, 2020
Cerevance Expands Series B Financing to $65 Million
Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April.
News Archive
October 7, 2026
Cerevance to Present Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease
- Solengepras 150 mg achieved a statistically significant reduction in daily OFF time, with benefit seen at Week 2
- Statistically significant improvements in secondary endpoints of ON time without troublesome dyskinesia and motor experiences of daily living (MDS-UPDRS Part II)
- Improvements in daytime sleepiness (Epworth Sleepiness Scale) and quality of life (PDQ-39, exploratory) point to broad motor and non-motor benefit
- Generally well tolerated, with fewer adverse events than those typically associated with dopaminergic adjunctive therapies, and a discontinuation rate similar to placebo
- Cerevance to meet with FDA to discuss the path to a potential New Drug Application
February 23, 2026
Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference
December 1, 2025
Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference
November 24, 2025
Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
Events Archive
October 30, 2026

A Binding Site for CVN293 Reveals a Mechanism for Allosteric Control of THIK-1 K2P Channel Gating
February 4, 2026

Discovery of Potent, Selective and Brain-Penetrant Small Molecule CD38 Inhibitors
October 21, 2024
CVN424, a GPR6 Inverse Agonist, for Parkinson’s Disease and Motor Fluctuations: A Double-Blind, Randomized, Phase 2 Trial
June 30, 2021




